Fig. 5

Prognostic performance of EXO1 expression in different LUAD patient subgroups. The LUAD patients were divided into different subgroups based on TMN stages, smoke, tumor status, age, gender and clinical stages. (A–D) The Cox regression analysis results show the prognostic performance of EXO1 expression levels regarding overall survival (A), disease-specific survival (B), disease free interval (C) and progression free interval (D) in different subgroups of LUAD patients. The results are represented by the hazard ratio (HR). The ends represented the 95% confidence interval (CI) of the HR values, and the positions of the diamonds represented the significance of the prognostic performance of EXO1.